Please see the impressive results from our most recent NUDGE trial 👇 from CTCPR Trials & CIRL presented by the talented Niklas Dyrby Johansen at ESCMID 2024. Stay tuned for the publication of the primary results very soon!

Sundhedsstyrelsen Tyra Grove Krause Statens Serum Inst. Department of Biomedical Sciences | UCPH Jonas Egebart UCPH Healthscience

Entresto has benefit in HFrEF but hypotension in HFpEF suggests less benefit in this group

“our data reinforce the benefit/risk ratio favors sacubitril/valsartan in patients with LVEF below normal, but not at higher LVEF”

jacc.org/doi/epdf/10.10…

British Society for Heart Failure #theFword PCCS

Awesome to present the main results of the NUDGE-FLU-CHRONIC trial as LBCT yesterday at #ESCMIDGlobal !

Our nudges increased flu vacc uptake from 28% to 40% in 18-64 yos with chronic diseases in Denmark, corresponding to 25,000 additional vaccinees!

Interesting analysis from PARAGON: As ejection fraction moves away from lower levels towards a higher range, patients with HFPEF tend to experience hypotension more frequently, leading to a higher risk of fatal and nonfatal events. #cardiotwitter #Cardiology #CardioEd

Niklas Dyrby Johansen from CTCPR Trials & CIRL presenting the results of our most recent NUDGE trial (NUDGE-FLU CHRONIC) during the LBCT session at ESCMID 2024. We presented the greatest ⬆️ in vaccine uptake displayed in any vaccine implementation trial to date (~11-14% increase in vaccine uptake).

🔴 Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction JACC Journals

✅jacc.org/doi/10.1016/j.…
#CardioEd #Cardiology #FOAMed #cardiotwiteros #MedEd #medtwitter what #medtwitter #CardioEd #CardioTwitter

⚠️Sacubitril/Valsartan-Related Hypotension in #PARAGON -HF

👥4,796 ▶️13% experienced hypotension, more frequently in the sacubitril/valsartan arm (P < 0.001)

👉hypotension, 🟰↗️ risk of CV☠️/🏥HF & all-cause ☠️

👉👥with LVEF ≥60% experienced substantially higher

Tipping the Scale Toward a More Accurate and Equitable Assessment of #HFrEF Pharmacotherapy Eligibility: A Call to Incorporate #Cystatin C in #eGFR

#CardioRenal European Society of Cardiology Journals Clyde Yancy, MD, MSc

onlinelibrary.wiley.com/doi/10.1002/ej… Shelley Zieroth BiykemBozkurt Javed Butler Joel M. Topf, MD FACP DenisFouque

Time to implement the #4pillars of “kidney GDMT”

- RAS blockade
- SGLT2i
- ns-MRA
- GLP-1 RA

Lifetime cardiovascular, kidney & mortality benefits of combination therapy in people with diabetes with albuminuria

Now #openaccess in Circulation for #AHA23

ahajournals.org/doi/10.1161/CI…

It was a privilege to present Norman Stockbridge with the 2024 HFC Lifetime Achievement Award for contributions to regulatory science, advocacy for the community without walls,and his disciplined integrity that has improved many pts. via CV and renal therapies.⁦Robert Harrington⁩

Contemporary American and European heart failure guidelines jacc.org/doi/abs/10.101… JACC Journals

Prior gains being lost in:

Older and younger
Females and males
Rural and urban
All race/ethnicities

#BalanceDHF Milestone❗️

First pts enrolled in #BalanceDHF RCT studying unique #MRmodulator balcinrenone in combo w #SGLT2i dapagliflozin

Seeking to expand therapeutic options in HF+CKD across the full spectrum of LVEF!

Long way to go, but 💪🏾 global team
classic.clinicaltrials.gov/ct2/show/NCT06…

🎉 20 years celebrations! 🎉

I look back with pride and a real sense of achievement as the #HFA_ESC has grown from a group of enthusiasts to a large respected scientific community influencing the field of #heartfailure .

It's all thanks to YOU!

Celebrate with us: comment, share

Super fun as always to join Freely Filtered: A NephJC Podcast - discussing all things FSGS, GFR slope / endpoint definitions, & lessons for next gen rare disease trials

Thanks Joel M. Topf, MD FACP Swapnil Hiremath @[email protected] Priya Yenebere Nayan Arora,MD Michelle Rheault for another fun episode

podcasts.apple.com/au/podcast/fre…

#nephjc

Contemporary American and European Guidelines for Heart Failure Management: #JACC : #HeartFailure Guideline Comparison

American College of Cardiology European Society of Cardiology Muthu Vaduganathan BiykemBozkurt

jacc.org/doi/full/10.10…

Muthu Vaduganathan Brendon Neuen Enrique Santas Paola Morejón Barragán Alfonso Valle Steve Greene BiykemBozkurt JACC Journals Janani Rangaswami Henry Han While benefit of steroidal MRAs may be attenuated at lower eGFR for certain outcomes, lower safety, and opportunity for improvement

benefits>>risks for:

eGFR 46-60
eGFR 31-45

jacc.org/doi/abs/10.101…

As part of the AHA Science Centennial Collection, Karen Joynt Maddox and I examine how major policy reforms in the US have impacted cardiovascular health

We also discuss opportunities to advance CV health & equity through policy, as well as emerging threats
ahajournals.org/doi/10.1161/CI…

Rich pipeline of alternative approaches to safely block MR axis being investigated in heart & kidney disease

🔥 K+ lowering therapies
🔥 Nonsteroidal MRAs
🔥 MR modulators
🔥 Aldosterone synthase inhibitors

👀 this rapidly changing space—upcoming HF RCTs to likely report '24 👇🏾

Effects of #GDMT across Kidney Function Spectrum

✅ #BB : consistent benefit to eGFR 30
✅ #ARNI : consistent benefit to eGFR 30
✅ #SGLT2i : consistent benefit to eGFR 20
❌ #SteroidalMRA : ↓ benefit & worse safety at lower eGFR

New strategies to block MR axis in HF & CKD needed!